文献速递脑血管病

活动性癌症患者缺血性卒中的分类与管理:美国心脏协会科学声明

Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association.
PubMed 文献 · Stroke · 2026-02-02

约10%至15%的缺血性卒中患者有癌症病史,其中半数在卒中时存在活动性恶性肿瘤。该科学声明综合多学科证据,提出将癌症本身所致的缺血性卒中定义为「癌症相关卒中」,并基于常规临床数据建立新的分类系统,按因果确定性及复发性血栓栓塞风险分层,以统一临床实践与研究命名。

要点

  • 活动性癌症患者约半数缺血性卒中为传统机制,其余为隐源性或癌症特异性机制。
  • 隐源性卒中具有特征性风险标志和临床特征,复发卒中及其他不良事件风险极高。
  • 新分类系统基于常规临床数据,按因果确定性和复发性血栓栓塞风险分层。

核心结论

  • 约10%至15%的缺血性卒中患者有癌症病史,其中半数在卒中时为活动性恶性肿瘤。
  • 活动性癌症患者约半数缺血性卒中由传统机制引起,其余为隐源性或癌症特异性机制。
  • 隐源性卒中具有特征性风险标志和临床特征,复发卒中及其他不良事件风险极高。
  • 新分类将癌症本身所致的缺血性卒中定义为癌症相关卒中,按因果确定性和复发性血栓栓塞风险分层。

研究设计与样本

  • 美国心脏协会科学声明,综合多学科专家对近期证据进行批判性评价与整合。

主要发现

  • 自2000年以来,随着癌症治疗改善延长患者生存,缺血性卒中与活动性癌症的共病率稳步增加。
  • 活动性癌症患者约半数缺血性卒中为传统机制,其余通常归类为隐源性或癌症特异性机制。
  • 隐源性卒中常具有特征性风险标志和临床特征,复发卒中及其他不良事件风险极高,区别于其他卒中亚组。
  • 近期流行病学、转化和組織病理学数据表明,许多此类事件可能由癌症本身通过多因素促血栓形成过程引起。

关键数值与推荐

  • 新分类系统基于常规可用的临床数据,包括因果确定性的不同类别,与患者独特临床特征和估计的复发性血栓栓塞风险相关。

临床怎么用

  • 建议采用癌症相关卒中的统一命名和分类框架,以 harmonize 临床实践与研究。
  • 该框架旨在推动专门对照试验,解决临床不确定性领域。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

About 10% to 15% of patients with ischemic stroke have a history of cancer, half of whom have active malignancy at the time of stroke. With improved cancer treatments extending patient survival, the coprevalence of these diseases has increased steadily since 2000. This has sparked considerable growth in research and knowledge on this topic. Approximately half of ischemic strokes in patients with active cancer are due to conventional mechanisms, although cancer-related factors may contribute. The remaining half of ischemic strokes in this population are typically classified as cryptogenic or attributed to cancer-specific mechanisms. These cryptogenic strokes often have characteristic risk markers and clinical features and are extremely high risk for recurrent stroke and other adverse events, distinguishing them from other stroke subgroups. Recent epidemiological, translational, and histopathological data indicate that many of these events are likely caused by the cancer itself through multifactorial prothrombotic processes. In this scientific statement incorporating multidisciplinary expertise, we critically appraise and synthesize recent evidence and provide clinical suggestions on the epidemiology, presentation, evaluation, pathophysiology, and treatments for ischemic stroke in patients with active cancer. In addition, we propose a novel classification for ischemic stroke attributed to cancer itself, which we define as cancer-related stroke to enable consistent nomenclature and to harmonize stroke classification across clinical practice and research. This system is based on routinely available clinical data and includes different categories for certainty of causality, relating to the patient's distinctive clinical features and estimated risk for recurrent thromboembolism. We hope this framework spurs dedicated controlled trials to address areas of clinical uncertainty.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Navi BB, Kasner SE, Cushman M, et al. Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association. Stroke. 2026. PMID: 41623113. doi:10.1161/STR.0000000000000517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。